| Not Yet Recruiting | This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autol NCT07412405 | GUSTAVO SALGUERO | N/A |
| Recruiting | Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP NCT07493109 | Ou Bai, MD/PHD | Phase 3 |
| Not Yet Recruiting | Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy NCT07463781 | Fondazione Italiana Linfomi - ETS | — |
| Recruiting | Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/B NCT07493148 | Ou Bai, MD/PHD | Phase 2 |
| Not Yet Recruiting | Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas NCT07478848 | Abramson Cancer Center at Penn Medicine | Phase 1 |
| Recruiting | Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous NCT07523737 | Beijing Tongren Hospital | Phase 2 |
| Not Yet Recruiting | Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL NCT07494565 | Sun Yat-sen University | Phase 2 |
| Not Yet Recruiting | Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large NCT06594939 | Medical College of Wisconsin | Phase 2 |
| Not Yet Recruiting | Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study NCT07398638 | Sun Yat-sen University | Phase 1 / Phase 2 |
| Recruiting | CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL NCT07397832 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy NCT07188558 | Lyell Immunopharma, Inc. | Phase 3 |
| Recruiting | Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation NCT07499271 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Not Yet Recruiting | Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma NCT07168291 | First Affiliated Hospital Xi'an Jiaotong University | EARLY_Phase 1 |
| Not Yet Recruiting | Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy NCT07310186 | Peking Union Medical College Hospital | — |
| Recruiting | A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma NCT07189065 | Guangzhou Lupeng Pharmaceutical Company LTD. | Phase 2 |
| Recruiting | Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cel NCT07371923 | Beijing Tongren Hospital | Phase 2 |
| Recruiting | Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma NCT07062627 | Hyungwoo Cho | Phase 2 |
| Recruiting | NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) NCT07502118 | Health Institutes of Turkey | Phase 2 / Phase 3 |
| Recruiting | Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma NCT07084662 | Sun Yat-sen University | Phase 2 / Phase 3 |
| Recruiting | A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lym NCT06828991 | Danielle Wallace | Phase 2 |
| Not Yet Recruiting | A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previ NCT07035379 | Zhejiang Teruisi Pharmaceutical Inc. | Phase 1 / Phase 2 |
| Recruiting | KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT07260812 | TCRx Therapeutics Co.Ltd | Phase 1 |
| Recruiting | A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma NCT07124936 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation NCT06793410 | Vastra Gotaland Region | Phase 2 |
| Recruiting | Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lym NCT07078500 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Recruiting | Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Opti NCT06050694 | University Health Network, Toronto | Phase 2 |
| Recruiting | A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma NCT06765317 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Not Yet Recruiting | The Microbiome in Blood Cancer and HLH NCT06734624 | University of Nottingham | — |
| Not Yet Recruiting | Dynamic CtDNA-guided Targeted Therapy in DLBCL NCT06748521 | Ruijin Hospital | Phase 2 |
| Recruiting | Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL NCT06682130 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Recruiting | Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial） NCT06647940 | Sun Yat-sen University | Phase 2 |
| Not Yet Recruiting | The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With R NCT06656234 | Ruijin Hospital | — |
| Not Yet Recruiting | Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BC NCT06652152 | Ruijin Hospital | — |
| Enrolling By Invitation | CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas NCT07168486 | University of Maryland, Baltimore | Phase 1 |
| Not Yet Recruiting | Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nerv NCT06594432 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Recruiting | Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy o NCT06832228 | Zhejiang Cancer Hospital | N/A |
| Recruiting | Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting As Indolent NCT06822829 | Azienda USL Reggio Emilia - IRCCS | — |
| Recruiting | Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma NCT06464861 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 1 |
| Recruiting | An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combinatio NCT06782789 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Recruiting | Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors NCT05934084 | Fondazione Italiana Linfomi - ETS | N/A |
| Active Not Recruiting | A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab NCT06091865 | Regeneron Pharmaceuticals | Phase 3 |
| Recruiting | Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms NCT06043011 | iOMEDICO AG | — |
| Completed | A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R NCT05665530 | Prelude Therapeutics | Phase 1 |
| Recruiting | Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients NCT07473167 | TICAROS Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas NCT05583149 | Patrick C. Johnson, MD | Phase 2 |
| Terminated | A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma NCT05720052 | MingSight Pharmaceuticals, Inc | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lym NCT05563844 | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 2 |
| Completed | A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus NCT05364424 | Hoffmann-La Roche | Phase 1 |
| Unknown | A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphom NCT05234684 | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 3 |
| Not Yet Recruiting | Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission NCT05596097 | LanZhou University | Phase 2 |
| Unknown | Multidimensional Assessment of Quality of Life, Social and Professional Life and Care Utilization in Patients NCT05532761 | Hospices Civils de Lyon | — |
| Completed | Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas. NCT07181785 | Andrés José Maria Ferreri | — |
| Active Not Recruiting | Pixantrone as Bridging Therapy to Allogenic Transplant or CAR-T Cell Therapy in DLBCL Patients NCT06760936 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Recruiting | Bio-CAR-T BS Study NCT05366569 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | — |
| Recruiting | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies NCT05131022 | Nurix Therapeutics, Inc. | Phase 1 |
| Terminated | Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell NCT04933617 | National Cancer Institute (NCI) | Phase 1 |
| Completed | IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II Study NCT07493486 | Zhejiang Cancer Hospital | Phase 2 |
| Withdrawn | Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgk NCT04456023 | Novartis Pharmaceuticals | Phase 2 |
| Terminated | A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) NCT05169489 | Regeneron Pharmaceuticals | Phase 1 |
| Active Not Recruiting | A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients NCT05189197 | Fudan University | Phase 2 |
| Recruiting | A Study of NX-1607 in Adults With Advanced Malignancies NCT05107674 | Nurix Therapeutics, Inc. | Phase 1 |
| Recruiting | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies NCT04830137 | Nurix Therapeutics, Inc. | Phase 1 |
| Completed | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies NCT04772989 | Arcus Biosciences, Inc. | Phase 1 |
| Terminated | GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies NCT04824794 | Genmab | Phase 1 / Phase 2 |
| Recruiting | Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients NCT04836507 | Curocell Inc. | Phase 1 / Phase 2 |
| Unknown | Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies NCT04767308 | Huazhong University of Science and Technology | EARLY_Phase 1 |
| Completed | Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T NCT04488354 | Calibr, a division of Scripps Research | Phase 1 |
| Completed | CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI) NCT05349201 | Novartis Pharmaceuticals | — |
| Completed | Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL) NCT05366257 | Novartis Pharmaceuticals | — |
| Completed | CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies NCT04450069 | Calibr, a division of Scripps Research | Phase 1 |
| Completed | Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-pre NCT05526313 | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 1 |
| Completed | A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or NCT04231747 | Juno Therapeutics, a Subsidiary of Celgene | Phase 1 |
| Completed | Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels NCT04537715 | Epizyme, Inc. | Phase 1 |
| Recruiting | Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Larg NCT03936153 | Xynomic Pharmaceuticals, Inc. | Phase 2 |
| Unknown | A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab Vedot NCT04624893 | Jiangsu Cancer Institute & Hospital | — |
| Active Not Recruiting | ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) NCT04049513 | Malaghan Institute of Medical Research | Phase 1 |
| Terminated | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Dif NCT03571828 | Amgen | Phase 1 |
| Terminated | A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML NCT03547115 | MEI Pharma, Inc. | Phase 1 |
| Completed | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies NCT03329950 | Celldex Therapeutics | Phase 1 |
| Terminated | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma NCT02914938 | MEI Pharma, Inc. | Phase 1 |
| Completed | A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated NCT02875548 | Epizyme, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous NCT02570542 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients NCT02445248 | Novartis Pharmaceuticals | Phase 2 |
| Terminated | A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combina NCT02957019 | Philogen S.p.A. | Phase 1 / Phase 2 |
| Active Not Recruiting | Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Im NCT01829958 | Memorial Sloan Kettering Cancer Center | N/A |
| Terminated | Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP NCT02983097 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | Phase 1 / Phase 2 |
| Unknown | DA-EDOCH14-R in Poor-prognosis Diffuse Large B-cell Lymphoma NCT01066429 | Hospital Universitario Principe de Asturias | Phase 2 |
| Completed | Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20 NCT01054781 | Samsung Medical Center | Phase 2 |
| Terminated | Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT NCT00482053 | Stanford University | Phase 2 |
| Completed | A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients NCT00400478 | Arbeitsgemeinschaft medikamentoese Tumortherapie | Phase 3 |
| Completed | R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL NCT01148446 | Fondazione Italiana Linfomi - ETS | Phase 3 |
| Completed | Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lympho NCT00001337 | National Cancer Institute (NCI) | Phase 2 |
| Available | A Compassionate Use (CU) Program of Odronextamab NCT05619367 | Regeneron Pharmaceuticals | — |
| Available | CTL019 Out of Specification MAP for ALL or DLBCL Patients NCT03601442 | Novartis Pharmaceuticals | — |
| Available | Karyopharm Expanded Access Program for Selinexor NCT07215832 | Karyopharm Therapeutics Inc | — |